GlassScriptPhysician profile
Michael Brooks
NPI 1881695039
$47,993.22
in general payments reported to CMS, 2019-2025
30 companies · $2,385 in 2025
The $2,385 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $8,985 · 2021: $587 · 2022: $7,815 · 2023: $8,537 · 2024: $1,464 · 2025: $2,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,600 · Food and Beverage: $4,890 · Travel and Lodging: $873 · Education: $23.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,600.00 |
| Food and Beverage | $4,889.97 |
| Travel and Lodging | $872.90 |
| Education | $23.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $23,813.51 | 2019-2025 | |
| Abbvie INC. | $16,486.22 | 2019-2025 | Linzess, Viberzi, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,276.20 | 2019-2025 | Xifaxan, Relistor, Plenvu |
| Janssen Biotech, INC. | $943.80 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $898.56 | 2019-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $512.34 | 2025 | Rezdiffra |
| Pfizer INC. | $356.07 | 2019-2025 | |
| Ardelyx, INC. | $293.72 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $232.67 | 2022-2025 | Dupixent |
| Celgene Corporation | $227.45 | 2023-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $172.30 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $166.37 | 2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $128.51 | 2019-2023 | Linzess |
| Evoke Pharma, INC. | $92.51 | 2023-2025 | Gimoti |
| Genzyme Corporation | $72.84 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $46.94 | 2023-2025 | Amjevita, Avsola |
| Redhill Biopharma INC. | $36.72 | 2021-2022 | |
| Novo Nordisk INC | $31.67 | 2025 | Wegovy |
| Allergan, INC. | $30.83 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $20.00 | 2020 | |
| Sandoz INC. | $19.64 | 2024 | Hyrimoz |
| Fresenius Kabi USA, LLC | $19.53 | 2023 | Idacio |
| Alnylam Pharmaceuticals INC. | $17.33 | 2025 | Givlaari |
| Qol Medical, LLC | $15.96 | 2025 | Sucraid |
| Endo Pharmaceuticals INC. | $15.85 | 2019 | |
| Braintree Laboratories, INC. | $15.66 | 2019 | |
| Boston Scientific Corporation | $15.39 | 2024 | |
| Intercept Pharmaceuticals, INC. | $13.16 | 2024 | |
| Nestle Healthcare Nutrition INC. | $12.23 | 2022 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.